Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PHIO | US
0.27
9.28%
Healthcare
Biotechnology
30/06/2024
21/10/2024
3.18
3.01
3.25
2.98
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762 INTASYL compound which reduces the expression of cell death Protein 1 (PD-1) a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4 a protein which controls gene expression in both T cells and tumor cells effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough Massachusetts.
View LessValue Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
163.2%1 month
124.9%3 months
107.2%6 months
105.7%-
0.31
0.66
-
-
0.61
172.20
-
-8.57M
2.74M
2.74M
-
-
-
-
-126.86
1.06
5.63
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.46
Range1M
1.46
Range3M
2.59
Rel. volume
0.37
Price X volume
135.57K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
SciSparc Ltd. Ordinary Shares | SPRC | Biotechnology | 0.29 | 3.00M | 26.53% | n/a | 1.00% |
Ensysce Biosciences Inc | ENSC | Biotechnology | 0.206 | 2.86M | 15.86% | n/a | 24.79% |
Cyclacel Pharmaceuticals Inc | CYCC | Biotechnology | 1.32 | 2.84M | 15.79% | n/a | 0.50% |
Salarius Pharmaceuticals Inc | SLRX | Biotechnology | 1.82 | 2.62M | -9.45% | n/a | 0.00% |
ZVSA | ZVSA | Biotechnology | 2.3 | 2.47M | 0.00% | 0.00 | 0.00% |
Dermata Therapeutics Inc. Common Stock | DRMA | Biotechnology | 1.56 | 2.36M | -3.11% | n/a | 0.00% |
Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.63 | 2.30M | -5.78% | n/a | 6.68% |
Altamira Therapeutics Ltd. | CYTO | Biotechnology | 0.5751 | 2.17M | -2.53% | 0.32 | 1.54% |
60 Degrees Pharmaceuticals Inc. Common Stock | SXTP | Biotechnology | 1.07 | 1.99M | -1.83% | n/a | 5.19% |
Sorrento Therapeutics Inc | SRNE | Biotechnology | 0.003 | 1.90M | 11.11% | n/a | -101.21% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.61 | 0.53 | Par |
Ent. to Revenue | 172.20 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.66 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 107.25 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 2.74M | 3.66B | Emerging |